胆酶抑制剂药物对记忆诊所患者QTc间隔的影响
Hanna Karita Isotalo1,2, Joanna Karoliina Lehtovaara3, Laura Linnea Ekblad1,2,4
1Department of Geriatric Medicine, Faculty of Medicine, Turku University Hospital, University of Turku, Turku, Finland.
The Annals of pharmacotherapy
|May 6, 2025
概括
用于阿尔茨海默病的胆酶抑制剂 (ChEIs) 在老年人中没有显著延长纠正的QT (QTc) 间隔. 这项研究没有发现心脏不良影响的风险增加,这表明目前的监测指南可能需要重新评估.
科学领域:
- 老年学是一门学科.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 胆酶抑制剂 (ChEIs),如多内佩西尔,里瓦斯蒂格明和胺是阿尔茨海默病的标准治疗方法.
- 对心脏不良影响存在担忧,特别是QT间隔延长,这是由于ChEIs对乙胆信号传递的影响.
- 目前的指导方针缺乏在ChEI治疗期间对心电图 (ECG) 监测的强有力的证据,之前的研究对纠正的QT (QTc) 间隔产生了不一致的发现.
研究的目的:
- 研究使用胆酶抑制剂 (ChEIs) 与老年人群中QTc间隔变化之间的关联.
- 为了确定ChEI启动是否导致QTc间隔的统计显著延长或病理QTc值的增加.
主要方法:
- 图尔库市医院对126名老年患者的心电图数据进行了回顾性分析,这些老年患者刚刚被处方ChEIs.
- 在CHEI治疗前和治疗期间测量了QTc间隔,其延长以性别特定的值定义 (女性≥460毫秒,男性≥450毫秒).
- 配对t测试和麦克纳马测试被用来比较QTc平均值和延长QTc间隔的比例,分别.
主要成果:
- 在使用登佩西尔,加兰他胺,里瓦斯蒂格明或所有ChEI组合时,在使用ChEI之前与使用ChEI期间的平均QTc间隔没有观察到统计学上显著的差异 (所有ChEI组合P > 0.13).
- 在CHEI治疗期间,QTc间隔延长的患者比例没有显著增加 (7.9%对12.7%,P=0.21).
- 个体ChEIs对平均QTc间隔或延长QTc的患病率没有显著影响.
结论:
- 在老年人中使用胆酶抑制剂与QTc间隔延长的统计显著增加无关.
- 该研究没有发现ChEI治疗期间病态QTc值比例增加的证据.
- 需要进行更大规模的研究,以建立基于证据的建议,以监测阿尔茨海默病ChEI治疗的患者的ECG.
相关概念视频
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
550
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
550
01:22Indirect-Acting Cholinergic Agonists: Pharmacokinetics
853
Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
853
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.5K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.5K
01:26Anticholinesterase Agents: Poisoning and Treatment
729
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
729
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
85
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
85
01:22Alzheimer's Disease: Treatment
125
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
125